 Oncternal Therapeutics, Inc. Nasdaq: ONCT, a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced an updated clinical strategy for its investigational ROR1 monoclonal antibody, cirmtuzumab, that prioritizes development in mantle cell lymphoma MCL, based on encouraging interim clinical results from the ongoing Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma CIRLL Phase 12 clinical trial that were presented at the American Society of Clinical Oncology 2020 Annual Meeting ASCO 2020 in May 2020. 